Whitehawk director granted stock, large warrant
Whitehawk Therapeutics director Caley Castelein reported new share and warrant awards.
Rhea-AI Filing Summary
Whitehawk Therapeutics director Caley Castelein reported new share and warrant awards. He received a grant of 255,102 shares of Common Stock at $3.92 per share, bringing his directly held Common Stock to 274,796 shares.
Entities associated with him, specifically KVP Capital, LP, now hold 2,165,998 shares of Common Stock indirectly and a Pre-Funded Warrant to acquire 2,072,756 additional Common shares at an exercise price of $0.0001 per share. The warrant can be exercised on or after May 14, 2026, but includes a 4.99% beneficial ownership cap. Castelein is Managing Director of KVP Capital and disclaims beneficial ownership in those indirect holdings except for his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,327,858 shares
Grant/Award
3 txns
Insider
Castelein Caley
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Pre-Funded Warrant (right to buy) | 2,072,756 | $8,124,996.24 as filed | -- |
| Grant/Award | Common Stock | 255,102 | $3.92 | $1000K |
| holding | Common Stock | -- | -- | -- |
- Price shown as filed: $8,124,996.24 per share is far above the $5.10 close on May 14, 2026, so no transaction value is shown.
Holdings After Transaction:
Pre-Funded Warrant (right to buy) — 2,072,756 contracts (Indirect, See footnote);
Common Stock — 274,796 shares (Direct);
Common Stock — 2,165,998 shares (Indirect, See footnote)
Footnotes (3)
- F1. Shares held by KVP Capital, LP. The Reporting Person is the Managing Director of KVP Capital. The Reporting Person disclaims beneficial ownership of shares held by KVP Capital, except to the extent of his pecuniary interest therein.
- F2. Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 14, 2026, exercise the Pre-Funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the holder cannot exercise any of the Pre-Funded Warrant to the extent the holder and its affiliates, including the Reporting Person, would beneficially own, after any such exercise, more than 4.99% of the outstanding Common Stock.
- F3. Pre-Funded Warrant held by KVP Capital, LP. The Reporting Person is the Managing Director of KVP Capital. The Reporting Person disclaims beneficial ownership of the Pre-Funded Warrant held by KVP Capital, except to the extent of his pecuniary interest therein.
Key Figures
Common Stock grant: 255,102 shares at $3.92
Direct Common Stock holding: 274,796 shares
Indirect Common Stock holding: 2,165,998 shares
+3 more
6 metrics
Common Stock grant
255,102 shares at $3.92
Award of Common Stock on May 14, 2026
Direct Common Stock holding
274,796 shares
Shares held directly after grant
Indirect Common Stock holding
2,165,998 shares
Common Stock held indirectly via KVP Capital, LP
Pre-Funded Warrant size
2,072,756 shares
Underlying Common Stock for Pre-Funded Warrant
Warrant exercise price
$0.0001 per share
Exercise price of Pre-Funded Warrant
Ownership cap
4.99% of outstanding Common Stock
Beneficial ownership limitation on warrant exercise
Key Terms
Pre-Funded Warrant, beneficial ownership, pecuniary interest, Managing Director, +1 more
5 terms
Pre-Funded Warrant financial
"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may..."
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
beneficial ownership financial
"the holder cannot exercise any of the Pre-Funded Warrant to the extent the holder and its affiliates... would beneficially own..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership... except to the extent of his pecuniary interest therein."
Managing Director financial
"The Reporting Person is the Managing Director of KVP Capital."
indirect ownership financial
"Pre-Funded Warrant held by KVP Capital, LP... The Reporting Person disclaims beneficial ownership..."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Whitehawk Therapeutics (WHWK) director Caley Castelein report?
Director Caley Castelein reported awards of Common Stock and a Pre-Funded Warrant. He received 255,102 Common shares at $3.92, plus an indirect Pre-Funded Warrant for 2,072,756 shares, alongside existing indirect holdings through KVP Capital, LP, as disclosed in the Form 4.
What are the key terms of the Pre-Funded Warrant reported for Whitehawk Therapeutics (WHWK)?
The Pre-Funded Warrant covers 2,072,756 shares of Common Stock at a $0.0001 exercise price. It is exercisable on or after May 14, 2026 and includes a 4.99% beneficial ownership limitation, restricting exercises that would push the holder’s stake above that level.
Who holds the indirect Whitehawk Therapeutics (WHWK) positions linked to Caley Castelein?
The indirect positions are held by KVP Capital, LP. Castelein is Managing Director of KVP Capital and disclaims beneficial ownership of its Common Stock and the Pre-Funded Warrant, except to the extent of his pecuniary interest in that investment entity.
Is the Common Stock reported in the Whitehawk Therapeutics (WHWK) Form 4 a market purchase or an award?
The 255,102 Common shares reported for Castelein are coded "A" as a grant or award. This indicates a compensation-related acquisition rather than an open-market purchase, and increased his directly held Common Stock to 274,796 shares after the transaction.
What ownership limitation applies to the Whitehawk Therapeutics (WHWK) Pre-Funded Warrant?
The Pre-Funded Warrant cannot be exercised if doing so would cause the holder and its affiliates, including Castelein, to beneficially own more than 4.99% of outstanding Common Stock. This contractual cap limits how much of the warrant can be exercised at any time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
